Evidence map›Paper›PMID 41339898›Full record

Trial reportBreast cancer research : BCR2025

M Chanchou, M A Mouret-Reynier, I Molnar, E Deshayes, V D'Hondt, K Bourahla, T Petit, S Bardet, C Levy, O Morel and 8 more

Registry-linked trialAbstract readClinical Trial, Phase IIMulticenter Study
PubMed Full text at PMC Publisher
In one paragraph

Trial report in Breast cancer research : BCR, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT02339532 (Neoadjuvant Phase II Trial Combining [3 FEC 100 Followed by 3 Docetaxel Associated With Trastuzumab Plus Pertuzumab] or [6 Docetaxel, Carboplatin Associated With Trastuzumab Plus Pertuzumab] According to TOP2A Status in Patients With T1c Operable, HER2-positive Breast Cancer), which is not on this map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT02339532 phase2completednot on this map

Neoadjuvant Phase II Trial Combining [3 FEC 100 Followed by 3 Docetaxel Associated With Trastuzumab Plus Pertuzumab] or [6 Docetaxel, Carboplatin Associated With Trastuzumab Plus Pertuzumab] According to TOP2A Status in Patients With T1c Operable, HER2-positive Breast Cancer

TypeinterventionalSponsorUNICANCERRan2015 to 2024Enrolled86ConditionsBreast CancerArmsFEC100, Docetaxel, Trastuzumab, Pertuzumab, Carboplatin
3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

18 authors.

M ChanchouUMR1240 IMoST. Médecine Nucléaire, Université Clermont Auvergne, CRLCC Jean Perrin, CRLCC Jean Perrin, 58 rue Montalembert, 63011, Clermont-Ferrand, France. marion.chanchou@clermont.unicancer.fr.ORCID http://orcid.org/0000-0002-2841-6994
M A Mouret-ReynierCRLCC Jean Perrin. Oncologie Médicale, CRLCC Jean Perrin, 58 rue Montalembert, 63011, Clermont-Ferrand, France.
I MolnarCRLCC Jean Perrin. Recherche Clinique, CRLCC Jean Perrin, 58 rue Montalembert, 63011, Clermont-Ferrand, France.ORCID http://orcid.org/0000-0001-5114-2648
E DeshayesMédecine nucléaire, institut du cancer de Montpellier (ICM), Université de Montpellier, 208, avenue des Apothicaires, 34298, Montpelliercedex 5, France.ORCID http://orcid.org/0000-0002-8408-4947
V D'HondtInstitut de recherche en cancérologie de Montpellier (IRCM), Université de Montpellier, institut régional du cancer de Montpellier (ICM), INSERM U1194, Montpellier, France.ORCID http://orcid.org/0000-0001-5238-4032
K BourahlaMédecine nucléaire et imagerie moléculaire, Centre Paul-Strauss, 3, rue de la Porte-de-l'Hôpital, 67000, Strasbourg, France.
T PetitOncologie médicale, Centre Paul Strauss, 3, rue de la Porte-de-l'Hôpital, 67000, Strasbourg, France.ORCID http://orcid.org/0000-0002-8746-0725
S BardetMédecine nucléaire, Centre François-Baclesse, 3, avenue Général-Harris, 14076, Caen cedex 05, France.ORCID http://orcid.org/0000-0002-1881-8674
C LevyOncologie médicale, Centre François-Baclesse, 3, avenue Général-Harris, 14076, Caen cedex 05, France.ORCID http://orcid.org/0000-0003-0572-5222
O MorelMédecine nucléaire, ICO Site Paul-Papin, 15, rue André-Bocquel, 49055, Angers cedex 2, France.ORCID http://orcid.org/0000-0002-3445-9632
P AugereauOncologie Médicale, ICO Site Paul-Papin, 15, rue André-Bocquel, 49055, Angers cedex 2, France.ORCID http://orcid.org/0000-0002-4748-0799
C RousseauMédecine Nucléaire, Institut de Cancérologie de l'Ouest, Nantes Université, Univ Angers, INSERM, CNRS, F-44800CRCI2NA, F-44000, Saint-HerblainNantes, France.ORCID http://orcid.org/0000-0002-0455-0523
M CamponeOncologie médicale, ICO Site René-Gauducheau, boulevard Jacques-Monod, 44805, Saint-Herblain cedex, France.ORCID http://orcid.org/0000-0002-5196-5908
J MonteilMédecine nucléaire, hôpital Dupuytren, CHU Limoges, 2, avenue Martin-Luther-King, 87042, Limoges cedex, France.ORCID http://orcid.org/0000-0002-7255-709X
L Venat-BouvetOncologie médicale, hôpital Dupuytren, CHU Limoges, 2, avenue Martin-Luther-King, 87042, Limoges cedex, France.
A FayeFaculté de Médecine, Université Clermont Auvergne, 28 place Henri Dunant, 63000, Clermont-Ferrand, France.ORCID http://orcid.org/0000-0002-1427-1827
V BenaventR&D UNICANCER, 101, rue de Tolbiac, 75654, Paris Cedex 13, France.
F CachinUMR1240 IMoST. Médecine Nucléaire, Université Clermont Auvergne, CRLCC Jean Perrin, CRLCC Jean Perrin, 58 rue Montalembert, 63011, Clermont-Ferrand, France.ORCID http://orcid.org/0000-0003-2171-1496

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

background

methodsWe collected data from patients enrolled in the prospective and multicentric French clinical trial NeoTOP (NCT02339532) who underwent

conclusions

Indexed as

Antineoplastic Combined Chemotherapy ProtocolsBreast NeoplasmsErb-b2 Receptor Tyrosine KinasesFluorodeoxyglucose F18Positron Emission Tomography Computed TomographyAdultAgedAntibodies, Monoclonal, HumanizedDocetaxelFemaleFranceHumansMiddle AgedNeoadjuvant TherapyPrognosisProspective StudiesAntibodies, Monoclonal, HumanizedDocetaxelERBB2 protein, humanErb-b2 Receptor Tyrosine KinasesFluorodeoxyglucose F18pertuzumabRadiopharmaceuticalsTrastuzumab18F–FDG PET–CTHER2+ BCNACpCR

Identifiers

PMID41339898
PMCPMC12781833

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.